Emergent BioSolutions secures $17M contract modification for oral suspension TEMBEXA
Source: SeekingAlpha
2025-09-15 08:54:29 ET
More on Emergent Biosolutions
- Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally
- Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful
- Mpox in Africa is no longer a global health emergency, WHO chief says
- Emergent Biosolutions awarded $30 million contract modification for CYFENDUS
Read the full article on Seeking Alpha
For further details see:
Emergent BioSolutions secures $17M contract modification for oral suspension TEMBEXA
Emergent Biosolutions Inc.
NASDAQ: EBS
EBS Trading
-1.31% G/L:
$8.30 Last:
154,342 Volume:
$8.26 Open:
EBS Latest News
March 03, 2026 08:00:00 am
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
February 26, 2026 04:05:00 pm
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026 04:01:00 pm
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness
February 26, 2026 04:01:00 pm
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
EBS Stock Data
$592,950,394
50,839,325
1.42%
58
N/A
Pharmaceuticals
Healthcare
US
Gaithersburg
